205 related articles for article (PubMed ID: 21390183)
1. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
[TBL] [Abstract][Full Text] [Related]
2. Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis.
Naran S; Abrams P; de Oliveira PQ; Hughes SJ
J Surg Res; 2011 Dec; 171(2):504-9. PubMed ID: 20934723
[TBL] [Abstract][Full Text] [Related]
3. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.
Hughes SJ; Nambu Y; Soldes OS; Hamstra D; Rehemtulla A; Iannettoni MD; Orringer MB; Beer DG
Cancer Res; 1997 Dec; 57(24):5571-8. PubMed ID: 9407969
[TBL] [Abstract][Full Text] [Related]
4. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells.
Reinehr R; Sommerfeld A; Häussinger D
Gastroenterology; 2008 May; 134(5):1494-506. PubMed ID: 18471522
[TBL] [Abstract][Full Text] [Related]
5. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H
J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131
[TBL] [Abstract][Full Text] [Related]
6. The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells.
Bourkoula K; Englert C; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2014 Jan; 134(2):291-300. PubMed ID: 23832418
[TBL] [Abstract][Full Text] [Related]
7. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
Fulda S; Strauss G; Meyer E; Debatin KM
Blood; 2000 Jan; 95(1):301-8. PubMed ID: 10607716
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR.
Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A
Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040
[TBL] [Abstract][Full Text] [Related]
9. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.
Mahidhara RS; Queiroz De Oliveira PE; Kohout J; Beer DG; Lin J; Watkins SC; Robbins PD; Hughes SJ
J Surg Res; 2005 Feb; 123(2):302-11. PubMed ID: 15680394
[TBL] [Abstract][Full Text] [Related]
10. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
11. CD95 Stimulation with CD95L and DISC Analysis.
Le Gallo M; Legembre P
Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
[TBL] [Abstract][Full Text] [Related]
13. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
16. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536
[TBL] [Abstract][Full Text] [Related]
18. CD95/Fas ligand induced toxicity.
Haluck-Kangas A; Peter ME
Biochem Soc Trans; 2023 Feb; 51(1):21-29. PubMed ID: 36629505
[TBL] [Abstract][Full Text] [Related]
19. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95.
Re D; Hofmann A; Wolf J; Diehl V; Staratschek-Jox A
Exp Hematol; 2000 Jan; 28(1):31-5. PubMed ID: 10658674
[TBL] [Abstract][Full Text] [Related]
20. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.
Moers C; Warskulat U; Müschen M; Even J; Niederacher D; Josien R; Koldovsky U; Beckmann MW; Häussinger D
Int J Cancer; 1999 Feb; 80(4):564-72. PubMed ID: 9935158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
